Creatinine-13C
Based on 1 Customer Validation
Creatinine-13C is the 13C-labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 1173022-95-1
- Formula: C313CH7N3O
- Molecular Weight:114.11
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1173022-95-1
-
Unlabeled Cas 60-27-5
-
Appearance Solid
-
Molecular Weight 114.11
-
Formula C313CH7N3O
-
Color White to off-white
-
SMILES
NC(N(C1)[13CH3])=NC1=O
-
Synonyms
NSC13123-13C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
H2O : 62.5 mg/mL (547.72 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Fang J, et al. Creatinine promotes adipose tissue wasting in chronic kidney disease via creatine and futile creatine cycle. Mol Metab. 2025;98:102191. [Content Brief]
[3]. Allen PJ, et al. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?. Neurosci Biobehav Rev. 2012;36(5):1442-1462. [Content Brief]
[4]. Polacheck I, et al. Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol. 1980;142(1):15-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 8.7635 mL | 43.8174 mL | 87.6347 mL | 219.0868 mL |
| 5 mM | 1.7527 mL | 8.7635 mL | 17.5269 mL | 43.8174 mL | |
| 10 mM | 0.8763 mL | 4.3817 mL | 8.7635 mL | 21.9087 mL | |
| 15 mM | 0.5842 mL | 2.9212 mL | 5.8423 mL | 14.6058 mL | |
| 20 mM | 0.4382 mL | 2.1909 mL | 4.3817 mL | 10.9543 mL | |
| 25 mM | 0.3505 mL | 1.7527 mL | 3.5054 mL | 8.7635 mL | |
| 30 mM | 0.2921 mL | 1.4606 mL | 2.9212 mL | 7.3029 mL | |
| 40 mM | 0.2191 mL | 1.0954 mL | 2.1909 mL | 5.4772 mL | |
| 50 mM | 0.1753 mL | 0.8763 mL | 1.7527 mL | 4.3817 mL | |
| 60 mM | 0.1461 mL | 0.7303 mL | 1.4606 mL | 3.6514 mL | |
| 80 mM | 0.1095 mL | 0.5477 mL | 1.0954 mL | 2.7386 mL | |
| 100 mM | 0.0876 mL | 0.4382 mL | 0.8763 mL | 2.1909 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz